康方生物(09926.HK) 继昨日(8日)急跌7.9%后,今早(9日)低开近6%,初段曾跌9%低见129.6元。现报132.8元,跌6.81%,成交313.69万股,涉资4.12亿元。康方生物的合作伙伴Summit Therapeutics(SMMT.US) 公布数据,令市场对其肺癌药物ivonescimab在美国的前景产生怀疑。公司早前指,该药物在后期试验中呈现出“持续改善的有利”总生存期...
Source Link康方生物(09926.HK) 继昨日(8日)急跌7.9%后,今早(9日)低开近6%,初段曾跌9%低见129.6元。现报132.8元,跌6.81%,成交313.69万股,涉资4.12亿元。康方生物的合作伙伴Summit Therapeutics(SMMT.US) 公布数据,令市场对其肺癌药物ivonescimab在美国的前景产生怀疑。公司早前指,该药物在后期试验中呈现出“持续改善的有利”总生存期...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.